Difei Yang
Stock Analyst at Mizuho
(2.14)
# 2,951
Out of 5,032 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $2.93 | -31.74% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $13.78 | +1,351.38% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.74 | +2,083.91% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $10.38 | +6,884.59% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $58.00 | -10.34% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $22.51 | +610.80% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $9.24 | +51.52% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $57.77 | +808.78% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.37 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $11.73 | +138.70% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.29 | +2,070.54% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $2.93
Upside: -31.74%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $13.78
Upside: +1,351.38%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.74
Upside: +2,083.91%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $10.38
Upside: +6,884.59%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $58.00
Upside: -10.34%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $22.51
Upside: +610.80%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $9.24
Upside: +51.52%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $57.77
Upside: +808.78%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.37
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $11.73
Upside: +138.70%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.29
Upside: +2,070.54%